Anixa Biosciences financials
$2.85+2.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Oct 31 | FY24 Oct 31 | FY23 Oct 31 | FY22 Oct 31 | FY21 Oct 31 | FY20 Oct 31 | FY19 Oct 31 | FY18 Oct 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $210.0K | $0.00 | $512.0K | $0.00 | $250.0K | $1.1M |
| Gross profit | $0.00 | $0.00 | $210.0K | $0.00 | $512.0K | $0.00 | $250.0K | $1.1M |
| Gross margin | — | — | 100.0% | — | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M | -$10.0M | -$11.9M | -$14.3M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M | -$10.0M | -$11.6M | -$14.0M |
| Net margin | — | — | −4671.9% | — | −2530.1% | — | −4658.8% | −1258.1% |
| Diluted EPS | $-0.34 | $-0.39 | $-0.32 | $-0.45 | $-0.45 | $-0.45 | $-0.59 | $-0.79 |
| EBITDA | -$11.7M | -$13.8M | -$11.0M | -$13.8M | -$13.1M | -$9.9M | -$11.0M | -$13.4M |
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M | -$6.2M | -$4.7M | -$4.3M |
| Free cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | — | -$6.2M | -$4.9M | -$4.3M |
| Diluted shares | 32.5M | 31.9M | 31.0M | 30.4M | 28.6M | 22.2M | 19.8M | 17.6M |
Balance sheet
| Period end | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.2M | $1.3M | $915.0K | $12.4M | $29.1M | $6.4M |
| Short-term investments | $13.9M | $18.7M | $22.9M | $17.3M | $6.6M | $2.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M | $9.5M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M | $1.2M |
| Shareholders' equity | $13.9M | $18.9M | $23.4M | $28.2M | $34.8M | $8.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology